chartexchange

FibroBiologics Reports Third Quarter 2026 Financial Results; Highlights Upcoming Catalysts

PR Newswire | Nov 16, 2026 4:13 PM EST

Initial safety data from Phase 1/2 CYWC628 diabetic foot ulcer trial expected in Q4 2026; interim efficacy data expected in Q1 2027 Issued patents increased 38% year to date to 170, with more than 325 issued and pending worldwide Total operating expenses decreased 19% year over year...

Read original article